List Biological Laboratories, Inc.

List Biological Laboratories, Inc. is a biotechnology company with a primary focus on harnessing bacteria's potential for a healthier world. Founded in 1978, the company is headquartered in the United States and has recently received a Venture Round investment at 01 January 2019 from Hana Ventures. Specializing in the production of native toxins, recombinant proteins, bacterial fermentation, assay development, contract manufacturing, and biotherapeutics, List Labs is known for its diverse product portfolio. The company's offerings include C. difficile toxin A and toxin B, shiga toxins, cholera toxin, anthrax toxins (PA, LF, and EF), pertussis toxin, diphtheria toxin, CRM197, tetanus toxin, staphylococcal enterotoxin B, botulinum toxins, as well as several types of lipopolysaccharides (LPS) or endotoxin for purchase by the research community. As an investor, the company's focus on biotechnology, production of vital toxins, and unique product offerings make it an intriguing option for investment within the ever-evolving biotech landscape. With a strong foundation and a clear commitment to leveraging bacteria's potential, List Biological Laboratories, Inc. presents a compelling case for potential investors seeking opportunities in the biotech sector.